Patents Assigned to Genentech
  • Pharmaceutical Compositions comprising Akt protein kinase inhibitors
    Publication number: 20180055845
    Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 1, 2018
    Applicant: Genentech, Inc.
    Inventors: REINHARD REENTS, PIRMIN HIDBER, ANDRE HELL, PETER STEIDLE, MARTIN WUNDERLICH, MARIE PEPELNJAK, FRANCIS GOSSELIN, EDWARD YOST
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180051010
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: February 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
    Patent number: 9895441
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Heather Maecker, Bryan Irving
  • Antibody purification by cation exchange chromatography
    Patent number: 9896478
    Abstract: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Benedicte Andree Lebreton, Deborah Ann O'Connor, Aurelia Safta, Mandakini Sharma
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 9896506
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals, including immunoconjugates comprising anti-CD79b cysteine-engineered antibody huMA79b.v28, and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • MUTANT SMOOTHENED AND METHODS OF USING THE SAME
    Publication number: 20180045729
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, mutations in the serpentine receptor, Smoothened (SMO) are described, which result in resistance to a Hedgehog (Hh) pathway inhibitor, such as in medulloblastoma. Amino acid substitutions in conserved residues of SMO maintain Hh signaling, but result in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. In some embodiments, the disclosure provides for novel mutant SMO proteins and nucleic acids and for screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 15, 2018
    Applicants: Genentech, Inc., Curis, Inc., Assistance Publique-Hopitaux de Paris, Universite Paris Diderot - Paris 7
    Inventors: Frederic J. DE SAUVAGE, Robert L. YAUCH, Gerrit J.P. DIJKGRAAF, Hayley SHARPE, Nicole BASSET-SEGUIN
  • ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20180044420
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 24, 2017
    Publication date: February 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20180044421
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 24, 2017
    Publication date: February 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants
    Patent number: 9890152
    Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: February 13, 2018
    Assignee: GENENTECH, INC.
    Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180037566
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.
    Type: Application
    Filed: July 7, 2017
    Publication date: February 8, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Daniel J. Burdick, Alexandre Cote, Martin Duplessis, Christopher G. Nasveschuk, Alexander M. Taylor
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20180037661
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20180037660
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20180037662
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
    Patent number: 9884919
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 6, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20180029984
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 1, 2018
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Nucleic acid molecules encoding for BACE1 antibodies
    Patent number: 9879094
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Genetic variations associated with drug resistance
    Patent number: 9879267
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Influenza A H7N9 virus therapies
    Patent number: 9879066
    Abstract: The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Ning Chai, Jacqueline McBride, Lee Swem